6 research outputs found
Multi-Level Considerations for Optimal Implementation of Long-Acting Injectable Antiretroviral Therapy to Treat People Living with HIV: Perspectives of Health Care Providers Participating in Phase 3 Trials
BACKGROUND: Long-acting injectable antiretroviral therapy (LA ART) has been shown to be non-inferior to daily oral ART, with high patient satisfaction and preference to oral standard of care in research to date, and has recently been approved for use in the United States and Europe. This study examined the perspectives of health care providers participating in LA ART clinical trials on potential barriers and solutions to LA ART roll-out into real world settings.
METHODS: This analysis draws on two data sources: (1) open-ended questions embedded in a structured online survey of 329 health care providers participating in the ATLAS-2 M trial across 13 countries; and (2) in-depth interviews with 14 providers participating in FLAIR/ ATLAS/ATLAS-2 M trials in the United States and Spain. Both assessments explored provider views and clinic dynamics related to the introduction of LA ART and were analyzed using thematic content analysis. The Consolidated Framework for Implementation Research (CFIR) was drawn on as the conceptual framework underpinning development of a model depicting study findings.
RESULTS: Barriers and proposed solutions to LA ART implementation were identified at the individual, clinic and health system levels. Provider perceptions of patient level barriers included challenges with adhering to frequent injection appointments and injection tolerability. Proposed solutions included patient education, having designated staff for clinic visit retention, and clinic flexibility with appointment scheduling. The main provider concern was identifying appropriate candidates for LA ART; proposed solutions focused on patient provider communication and decision making. Clinic level barriers included the need for additional skilled individuals to administer injections, shifts in workflow as demand increases and the logistics of cold-chain storage. Proposed solutions included staff hiring and training, strategic planning around workflow and logistics, and the possibility of offering injections in other settings, including the home. Health system level barriers included cost and approvals from national regulatory bodies. Potential solutions included governments subsidizing treatment, ensuring cost is competitive with oral ART, and offering co-pay assistance.
CONCLUSIONS: Results suggest the importance of multi-level support systems to optimize patient-provider communication and treatment decision-making; clinic staffing, workflow, logistics protocols and infrastructure; and cost-related factors within a given health system
Oral immunogenicity in mice and sows of enterotoxigenic escherichia coli outer-membrane vesicles incorporated into zein-based nanoparticles
Enterotoxigenic Escherichia coli (ETEC) strains are a major cause of illness and death in
neonatal and recently weaned pigs. The immune protection of the piglets derives from maternal
colostrum, since this species does not receive maternal antibodies through the placenta. In the
present study, outer membrane vesicles (OMVs) obtained from main ETEC strains involved in
piglet infection (F4 and F18 serotypes), encapsulated into zein nanoparticles coated with Gantrez®®
AN-mannosamine conjugate, were used to orally immunize mice and pregnant sows. Loaded
nanoparticles were homogeneous and spherical in a shape, with a size of 220–280 nm. The diffusion of
nanoparticles through porcine intestinal mucus barrier was assessed by a Multiple Particle Tracking
technique, showing that these particles were able to diffuse efficiently (1.3% diffusion coefficient),
validating their oral use. BALB/c mice were either orally immunized with free OMVs or encapsulated
into nanoparticles (100 µg OMVs/mouse). Results indicated that a single dose of loaded nanoparticles
was able to elicit higher levels of serum specific IgG1, IgG2a and IgA, as well as intestinal IgA, with
respect to the free antigens. In addition, nanoparticles induced an increase in levels of IL-2, IL-4 and
IFN-Îł with respect to the administration of free OMVs. Orally immunized pregnant sows with the
same formulation elicited colostrum-, serum- (IgG, IgA or IgM) and fecal- (IgA) specific antibodies
and, what is most relevant, offspring suckling piglets presented specific IgG in serum. Further studies
are needed to determine the infection protective capacity of this new oral subunit vaccin
Oral immunogenicity in mice and sows of enterotoxigenic escherichia coli outer-membrane vesicles incorporated into zein-based nanoparticles
Enterotoxigenic Escherichia coli (ETEC) strains are a major cause of illness and death in
neonatal and recently weaned pigs. The immune protection of the piglets derives from maternal
colostrum, since this species does not receive maternal antibodies through the placenta. In the
present study, outer membrane vesicles (OMVs) obtained from main ETEC strains involved in
piglet infection (F4 and F18 serotypes), encapsulated into zein nanoparticles coated with Gantrez®®
AN-mannosamine conjugate, were used to orally immunize mice and pregnant sows. Loaded
nanoparticles were homogeneous and spherical in a shape, with a size of 220–280 nm. The diffusion of
nanoparticles through porcine intestinal mucus barrier was assessed by a Multiple Particle Tracking
technique, showing that these particles were able to diffuse efficiently (1.3% diffusion coefficient),
validating their oral use. BALB/c mice were either orally immunized with free OMVs or encapsulated
into nanoparticles (100 µg OMVs/mouse). Results indicated that a single dose of loaded nanoparticles
was able to elicit higher levels of serum specific IgG1, IgG2a and IgA, as well as intestinal IgA, with
respect to the free antigens. In addition, nanoparticles induced an increase in levels of IL-2, IL-4 and
IFN-Îł with respect to the administration of free OMVs. Orally immunized pregnant sows with the
same formulation elicited colostrum-, serum- (IgG, IgA or IgM) and fecal- (IgA) specific antibodies
and, what is most relevant, offspring suckling piglets presented specific IgG in serum. Further studies
are needed to determine the infection protective capacity of this new oral subunit vaccin
Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials
Background: Long-acting injectable antiretroviral therapy (LA ART) has been shown to be non-inferior to daily oral ART, with high patient satisfaction and preference to oral standard of care in research to date, and has recently been approved for use in the United States and Europe. This study examined the perspectives of health care providers participating in LA ART clinical trials on potential barriers and solutions to LA ART roll-out into real world settings. Methods: This analysis draws on two data sources: (1) open-ended questions embedded in a structured online survey of 329 health care providers participating in the ATLAS-2 M trial across 13 countries; and (2) in-depth interviews with 14 providers participating in FLAIR/ ATLAS/ATLAS-2 M trials in the United States and Spain. Both assessments explored provider views and clinic dynamics related to the introduction of LA ART and were analyzed using thematic content analysis. The Consolidated Framework for Implementation Research (CFIR) was drawn on as the conceptual framework underpinning development of a model depicting study findings. Results: Barriers and proposed solutions to LA ART implementation were identified at the individual, clinic and health system levels. Provider perceptions of patient level barriers included challenges with adhering to frequent injection appointments and injection tolerability. Proposed solutions included patient education, having designated staff for clinic visit retention, and clinic flexibility with appointment scheduling. The main provider concern was identifying appropriate candidates for LA ART; proposed solutions focused on patient provider communication and decision making. Clinic level barriers included the need for additional skilled individuals to administer injections, shifts in workflow as demand increases and the logistics of cold-chain storage. Proposed solutions included staff hiring and training, strategic planning around workflow and logistics, and the possibility of offering injections in other settings, including the home. Health system level barriers included cost and approvals from national regulatory bodies. Potential solutions included governments subsidizing treatment, ensuring cost is competitive with oral ART, and offering co-pay assistance. Conclusions: Results suggest the importance of multi-level support systems to optimize patient-provider communication and treatment decision-making; clinic staffing, workflow, logistics protocols and infrastructure; and cost-related factors within a given health system